Viken, Sweden – November 9, 2010 – TikoMed AB, a biotechnology company focused on development and commercialization of innovative treatments for immune diseases and transplantation therapies, today announced that it will cooperate with Prof. Robert Rieben at Bern University, Switzerland. The aim is to develop new treatments for reduction of reperfusion injury and tissue damage associated to transplantation and other applications, by repairing injured tissues, inhibiting destructive immunological reactions and stimulate growth factors.
”We look forward to the collaboration with Prof. Rieben, a world authority in the research of reperfusion injury, and hope that this collaboration can deliver additional treatments in the area of transplantation and potentially other indications, said Anders Waas, CEO of TikoMed”.
Swedish-based TikoMed is an innovation driven biotechnology company focused on the development and commercialization of novel treatments for transplantation therapies and immune diseases. Currently, TikoMed has three products in development:
- IBsolvMIR/Diabetes, a treatment to improve islet cell transplantation for patients with severe type 1 diabetes. An ongoing Phase II clinical study has gained a $15 million grant from the National Institutes of Health (NIH)
- IBsolvMIR/BMT, a treatment to improve the outcome of bone-marrow transplantations and reduce complications through improving the engraftment of the cell transplantation. There is a high unmet need to improve bone-marrow transplantations, with globally more than 50 000 performed yearly.
- TM-120, is an apheresis product for autoimmune and inflammatory diseases. It binds and down regulates IP-10, a pro-inflammatory chemokine. It will first be developed for rheumatoid arthritis. The market for treatment of rheumatism is larger than $8 billion and there is a significant unmet need for improved treatments.
For more information, please visit www.tikomed.com.
Anders Waas (CEO)
Adam Bruce (Chairman of the board)